Screener
Boston Scientific BSX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $5.44B+7.5% | $5.2B+11.6% | $5.29B+15.9% | $5.07B+20.3% | $5.06B+22.8% | ||
| $1.59B-2.6% | $1.59B+9.4% | $1.61B+9.7% | $1.52B+16.1% | $1.64B+28.9% | ||
| $3.85B+12.4% | $3.61B+12.6% | $3.68B+18.8% | $3.54B+22.3% | $3.42B+20.1% | ||
| 70.7%+3.1pp | 69.4%+0.6pp | 69.6%+1.7pp | 69.9%+1.1pp | 67.7%-1.5pp | ||
| $1.8B+5.1% | $1.78B+11.5% | $1.83B+13.8% | $1.74B+11.5% | $1.72B+18.7% | ||
| —— | $2.51B+9.8% | $2.85B+17.9% | $2.49B+15.2% | $2.61B+11.8% | ||
| $1.18B+43.8% | $1.1B+19.5% | $825M+22.2% | $1.05B+43.0% | $819M+57.5% | ||
| 21.6%+5.5pp | 21.2%+1.4pp | 15.6%+0.8pp | 20.7%+3.3pp | 16.2%+3.6pp | ||
| -$96M-207% | $90M+9.8% | $90M+12.5% | $87M+10.1% | $90M+16.9% | ||
| $1.06B+12.6% | $1.16B+44.3% | $700M+19.7% | $939M+40.4% | $941M+124% | ||
| $155M+6.2% | -$176M-232% | $30M+30.4% | $183M-8.5% | $146M+49.0% | ||
| $907M+14.1% | $1.34B+99.3% | $670M+19.2% | $755M+61.3% | $795M+147% | ||
| 16.7%+1.0pp | 25.7%+11.3pp | 12.7%+0.4pp | 14.9%+3.8pp | 15.7%+7.9pp | ||
| $0.61+15.1% | $0.90+100% | $0.45+18.4% | $0.51+59.4% | $0.53+141% | ||
| $1.18B+43.8% | $1.1B+19.5% | $825M+22.2% | $1.05B+43.0% | $819M+57.5% |
FAQ
- What is Boston Scientific's revenue?
- Boston Scientific (BSX) generated $21.0B in revenue over the trailing twelve months, up 13.5% year over year.
- Is Boston Scientific profitable?
- Boston Scientific reported $3.7B in net income over the trailing twelve months, a 17.5% net margin.
- What are Boston Scientific's profit margins?
- Gross margin is 69.9% and operating margin is 19.8%, with a 17.5% net margin.
- What is Boston Scientific's earnings per share?
- Boston Scientific's diluted EPS over the trailing twelve months is $2.47.
- Where does Boston Scientific's income statement data come from?
- Every line is extracted from Boston Scientific's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
